Terranova, Remi (2011) Novartis: Genedata Expressionist® for Genomic Profiling used to predict effects of non-genotoxic carcinogens. Case study document from genedata company.

Abstract

Drug development efficiency can increase significantly when undesired side effects of drug candidates are detected early in development. Today, less than ten percent of all drug candidates entering clinical studies complete clinical development due to drug safety issues. To identify these issues as early as possible and share research findings with a broad community, Novartis researchers use Genedata Expressionist for Genomic Profiling. Genedata Expressionist creates a novel method for identifying biomarkers that can predict the effects of non-genotoxic carcinogens (NGCs). Moreover, this profiling method enables early detection of drug-induced tumor formation and better safety assessment of drug candidates.

Item Type:	Article
Date Deposited:	13 Oct 2015 13:14
Last Modified:	13 Oct 2015 13:14
URI:	https://oak.novartis.com/id/eprint/6519